Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDV-targeted PNU-159682 plus EDV-GC for advanced pancreatic and other EGFR-expressing solid tumors
ACTRN12619000385145Phase 2Terminated
- Sponsor
- EnGeneIC
- Start
- Mar 2019
- Modality
- Nanoparticles → Drug Delivery Systems, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of EGFR(V)-EDV-PNU and EDV-GC in pancreatic cancer (PC) and Nonhematologic neoplasms (2 cohorts), sponsored by EnGeneIC. Primary endpoints: Safety and tolerability, Anti-tumor response and 1 more. Started Mar 2019; status: terminated.
02
Drugs
EGFR(V)-EDV-PNUEDV-GC
03
Conditions
pancreatic cancer (PC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12619000385145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000385145.